Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aytu Biopharma (AYTU) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Aytu Biopharma (AYTU) over the last 17 years, with Q2 2025 value amounting to $0.01.

  • Aytu Biopharma's EPS (Basic) rose 10120.4% to $0.01 in Q2 2025 from the same period last year, while for Jun 2025 it was $0.01, marking a year-over-year increase of 10034.52%. This contributed to the annual value of $0.1 for FY2025, which is 10345.21% up from last year.
  • Per Aytu Biopharma's latest filing, its EPS (Basic) stood at $0.01 for Q2 2025, which was up 10120.4% from -$0.82 recorded in Q2 2024.
  • Aytu Biopharma's 5-year EPS (Basic) high stood at $0.01 for Q2 2025, and its period low was -$35.9 during Q1 2022.
  • Its 5-year average for EPS (Basic) is -$5.75, with a median of -$1.12 in 2021.
  • In the last 5 years, Aytu Biopharma's EPS (Basic) tumbled by 611714.29% in 2021 and then soared by 10120.4% in 2025.
  • Quarter analysis of 5 years shows Aytu Biopharma's EPS (Basic) stood at -$8.74 in 2021, then soared by 75.4% to -$2.15 in 2022, then skyrocketed by 92.93% to -$0.15 in 2023, then tumbled by 439.27% to -$0.82 in 2024, then skyrocketed by 101.2% to $0.01 in 2025.
  • Its EPS (Basic) stands at $0.01 for Q2 2025, versus -$0.82 for Q2 2024 and -$0.11 for Q1 2024.